Multiple angiogenesis-related signaling components

Multiple angiogenesis-related signaling components refers to a complex network of proteins and pathways that coordinate the physiological and pathological formation of new blood vessels. This network primarily includes the Vascular Endothelial Growth Factor (VEGF) family and its receptors (VEGFR-1, -2, -3), Platelet-Derived Growth Factor (PDGF) and its receptors (PDGFR-alpha, -beta), Fibroblast Growth Factor (FGF) pathways, and the Tie/Angiopoietin system [1][2]. In oncology, these components are critical for tumor growth beyond a few millimeters, as they facilitate the recruitment of blood vessels to provide nutrients and oxygen [3]. These pathways also play significant roles in non-oncological conditions such as age-related macular degeneration and diabetic retinopathy, where excessive vessel growth leads to vision loss [4]. Therapeutic strategies often involve multi-kinase inhibitors (MKIs) or monoclonal antibodies that simultaneously block several of these receptors to overcome redundant signaling and resistance [5]. By inhibiting these targets, drugs can effectively starve tumors of their blood supply and inhibit metastasis [6]. However, because these signaling components are also involved in maintaining normal vascular health, their inhibition can lead to systemic side effects like hypertension, proteinuria, and delayed wound healing [7].

Other names

Angiogenic signaling pathwaysPro-angiogenic factorsMulti-kinase targetsAngiogenesis signaling networkVascular signaling components

Inhibition of multiple receptor tyrosine kinases (RTKs) and downstream intracellular signaling cascades (such as MAPK/ERK and PI3K/Akt) to prevent endothelial cell activation, proliferation, and migration, thereby disrupting the formation of new blood vessels.